Retatrutide 10mg vial

GLP-1 / incretin

What is Retatrutide?

Last updated: 29 October 2026

An investigational single peptide that activates three receptors at once: GIP, GLP-1 and glucagon. Code name LY3437943.

Triple incretin agonistInvestigational · not approved
Class
Triple incretin/glucagon receptor agonist
Also known as
LY3437943
Type
Acylated synthetic peptide
Research stage
Late-stage clinical trials; not an approved medicine

01 · Classification

What it is

Retatrutide is a synthetic peptide built on a GIP-like backbone and modified so that one molecule binds three related receptors: the GIP receptor, the GLP-1 receptor and the glucagon receptor. A fatty-acid side chain lets it bind albumin in the blood, which gives it a long half-life in study models.

It is one of several "multi-agonist" incretin compounds now in development. Because it hits three targets, it is used in research comparing single, dual and triple receptor activation.

02 · Mechanisms

What has been studied

  • GLP-1 receptor: studied for its effects on insulin secretion, gastric emptying and central signalling.
  • GIP receptor: the second incretin pathway, studied alongside GLP-1 for additive metabolic effects.
  • Glucagon receptor: studied for its role in energy expenditure and hepatic lipid metabolism, which is what sets triple agonists apart from dual agonists.

03 · Evidence

Where the research is

Phase 2 clinical results have been published in peer-reviewed journals, and phase 3 programmes are under way. It is not approved by the FDA. Research-grade material is a laboratory reagent, not a clinical product.

04 · Primary sources

Read the literature

Search the primary research record directly rather than relying on summaries, including this one.

Research use only

Supplied strictly for laboratory and educational research. Not a drug, not for human or veterinary use, and not evaluated by the FDA. This overview is not medical advice and gives no dosing or administration guidance.

← All research overviews